Pharmaceutical companies have invested hundreds of millions of dollars in developing disease-modifying drugs, including monoclonal antibodies, inhibitors (e.g., aducanumab, donanemab, donepezil, memantine), while neurologists, psychiatrists, foundations, families, and affected individuals continue to await a transformative therapeutic breakthrough (Knopman et al., 2021)
This is a common hurdle, but it's one we can absolutely manage
Cartoon illustrations were created using BioRender.com
This data helps your PlexusDx provider optimize timing and dosing beyond generic interaction guidelines
While brands like Breakstones spent decades trying to convince us to love the lumps, consumers realized the lumps were a bug, not a feature
Nevertheless, no inhibitor has yet reached phase I clinical trials and further efforts are needed to circumvent all obstacles related to absorption, metabolism and various issues on pharmacokinetics in order to eventually achieve orally bioavailable drug candidates acting as cognitive enhancers in vivo
